UKUK

New biotech site

06.02.2011

Brussels – UCB Group S.A. announced in late December of 2010 that it has initiated a project to build an in-house biotech microbial manufacturing capacity in Bulle (Switzerland) to secure demand for its core product Cimzia (certoluzimab pegol). Slated to go online in 2015, the new manufacturing unit requires an investment of EUR250m. “We want to be able to meet our projected future demand for 2015 and beyond for Cimzia – by adding internal capacity to our existing ones,” says Michele Antonelli, UCB’s Executive Vice President. “Together with a pilot-plant under construction in Braine l’Alleud (Belgium), UCB wants to strengthen its ability to deliver biological products.”

UKUK

23.08.2011

London - GlaxoSmithKline has invested about €1.5m to take a 25.4 percent stake in Autifony Therapeutics, a British biotechnology company spun out of GSK to research treatments for tinnitus and hearing loss. Autifony’s other...

UKUK

19.08.2011

Brussels – While worldwide stock exchanges took a beating in late July and early August, European biotech stocks plunged even more. Stocks of majors like Roche, Novartis and GSK lost more than 10% in the first week of the month,...

Austria, UKUK

17.08.2011

London/Pasching –GE Healthcare vamps up its biopharmaceutical capabilities. The U.K. based unit of the U.S. technology giant General Electric, announced that it has reached an agreement to acquire the Austrian PAA Laboratories....

UKUK

16.08.2011

London – The International Multiple Sclerosis Genetics Consortium, led by the Universities of Cambridge and Oxford and funded by the Wellcome Trust, has identified 29 new genetic variations linked to multiple sclerosis (MS). The...

UKUK

16.08.2011

London – A consortium led by British gene medicince company Ark Therapeutics Group plc has received a EUR5.3m grant from the European Commission’s 7th Framework Programme to fund research to combine Ark’s technology covering...

UKUK

09.08.2011

London - Patents on biomarkers are necessary to encourage innovation and investment in the UK DNA diagnostics market. This is the conclusion of a report from the UK Human Genetics Commission. The paper "Intellectual Property and...

UKUK

15.07.2011

London/Rockville - GlaxoSmithKline and its American partner Human Genome Sciences, Inc. announced today that the European Commission has granted marketing authorisation for belimumab (Benlysta) as an add-on therapy in adult...

UKUK

07.07.2011

The British analytics specialist LGC Ltd. will buy its peer, KBioscience, for an undisclosed sum. The acquisition of KBioscience brings LGC expertise in genotyping services, chemistry and complements its genomic services...

Displaying results 31 to 40 out of 396

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/3/article/new-biotech-site.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.97 EUR11.43%
  • PROSENSA (NL)10.24 USD5.89%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK5.71%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • STENTYS (F)7.26 EUR-12.32%

TOP

  • WILEX (D)2.70 EUR221.4%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK49.8%
  • Allergy Therapeutics (UK)20.00 GBP33.3%

FLOP

  • HYBRIGENICS (F)1.68 EUR-28.5%
  • METABOLIC EXPLORER (F)2.88 EUR-21.3%
  • VITA 34 (D)4.16 EUR-20.6%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)418.50 GBP634.2%
  • PAION (D)2.50 EUR290.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.0%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-71.0%

No liability assumed, Date: 01.08.2014


Current issue

All issues

Product of the week

Products